Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical AB-101 Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis With or Without Secondary Cutaneous Infection

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical AB-101 Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis With or Without Secondary Cutaneous Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 101 Alphyn Biologics (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alphyn Biologics

    • Most Recent Events

    • 10 Mar 2025 According to an Alphyn Biologics media release, company to present data from this study in a poster presentation at the American Academy of Dermatology (AAD) annual meeting.
    • 10 Mar 2025 Results presented in the Alphyn Biologics Media Release.
    • 10 Dec 2024 Status changed from active, no longer recruiting to completed, according to an Alphyn Biologics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top